Asosiy kontentga oʻtish
Sharh maqola

Treatment and outcomes in children with multidrug-resistant tuberculosis: A systematic review and individual patient data meta-analysis

Elizabeth HarauszMilitary HIV Research Program, Bethesda, Maryland, United States of AmericaAnthony J. Garcia‐PratsDesmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Tygerberg, South AfricaStephanie J. LawMontreal Chest Institute, McGill University, Montreal, Quebec, CanadaH. Simon SchaafDesmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Tygerberg, South AfricaTamara KredoCochrane South Africa, South African Medical Research Council, Cape Town, South AfricaJames A. SeddonCentre for International Child Health, Imperial College, London, United KingdomDick MenziesMontreal Chest Institute, McGill University, Montreal, Quebec, CanadaAnna TurkovaImperial College Healthcare NHS Trust, Institute of Clinical Trials and Methodology, London, United KingdomJay AcharManson Unit, Médecins Sans Frontières (MSF), London, United KingdomFarhana AmanullahThe Indus Hospital, Karachi, PakistanPennan M. BarryCalifornia Department of Public Health, Sacramento, California, United States of AmericaMercedes C. BecerraPartners In HealthEdward D. ChanDenver Veterans Affairs Medical Center, National Jewish Health, Denver, Colorado, United States of AmericaPei‐Chun ChanDivision of Chronic Infectious Disease, Centers for Disease Control, Taipei, TaiwanDomnica Ioana ChiotanAldo CrossaNew York City Department of Health and Mental Hygiene, New York, New York, United States of AmericaPeter DrobacPartners In HealthLee FairlieWits Reproductive Health & HIV Institute (WRHI), University of the Witwatersrand, Johannesburg, South AfricaDennis FalzonLaboratories, Diagnostics and Drug Resistance Unit, Global TB Programme, World Health Organization, Geneva, SwitzerlandJennifer FloodCalifornia Department of Public Health, Sacramento, California, United States of AmericaMedea GegiaTechnical Support Coordination, Global TB Programme, World Health Organization, Geneva, SwitzerlandRobert M. HicksAlbert Einstein College of Medicine, Bronx, New York, United States of AmericaPetros IsaakidisMédecins Sans Frontières (MSF)/Doctors Without Borders, Mumbai, IndiaSM KadriBeate KampmannPaediatric Infection & Immunity, Centre of International Child Health, Imperial College London, London, United KingdomShabir A. MadhiMedical Research Council: Respiratory and Meningeal Pathogens Research Unit, and Department of Science and Technology/National Research Foundation: Vaccine Preventable Diseases, University of the Witwatersrand, Johannesburg, South AfricaElsé MaraisDepartment of Clinical Microbiology and Infectious Diseases, University of the Witwatersrand and the National Health Laboratory Services, Johannesburg, South AfricaAndrei MariandyshevNorthern State Medical University, Arkhangelsk, Russian FederationAna Méndez‐EchevarríaPediatric, Infectious and Tropical Diseases Department, Hospital La Paz, Madrid, SpainBrittany K. MooreDivision of Global HIV and TB, U.S. Centers for Disease Control and Prevention, Atlanta, Georgia, United States of AmericaParpieva NargizaRepublican Scientific Medical Center of Phtiziology and Pulmonology, Ministry of Health, Tashkent, UzbekistanIveta OzereRiga Eastern Clinical University Hospital, Centre for Tuberculosis and Lung Diseases, Riga, LatviaNesri PadayatchiCAPRISA, MRC TB-HIV Pathogenesis Unit, Durban, South AfricaSaleem- ur-RehmanNatasha RybakAlpert Medical School of Brown University, Providence, Rhode Island, United States of AmericaBegoña SantiagoPediatric Infectious Diseases Unit, Instituto de Investigación Sanitaria Gregorio Marañón, Hospital General Universitario Gregorio Marañón, Madrid, SpainNeha ShahAlbert Einstein College of Medicine, Bronx, New York, United States of AmericaSangeeta SharmaDepartment of Pediatrics, National Institute of Tuberculosis and Respiratory Diseases, New Delhi, IndiaTae Sun ShimUniversity of UlsanAlena M. SkrahinaThe Republican Research and Practical Centre for Pulmonology and TB, Minsk, BelarusAntoni Soriano‐ArandesPediatric Infectious Diseases and Immunodeficiencies Unit, Unit of International Health-Tuberculosis Drassanes-Vall Hebron, Hospital Universitari Vall d'Hebron, Barcelona, SpainMartin van den BoomWorld Health Organization - DenmarkMarieke J. van der WerfDisease Programme Tuberculosis, European Centre for Disease Prevention and Control, Stockholm, SwedenTjip S. van der WerfUniversity Medical Center Groningen, Groningen, the NetherlandsBhanu WilliamsNorthwick Park HospitalElena YablokovaNorthern State Medical University, Arkhangelsk, Russian FederationJae‐Joon YimDivision of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, South KoreaJennifer FurinDepartment of Global Health and Social Medicine, Harvard Medical School, Boston, Massachusetts, United States of AmericaAnneke C. HesselingDesmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Tygerberg, South Africafor the Collaborative Group for Meta-Analysis of Paediatric Individual Patient Data in MDR-TB
2018en
ABI

Annotatsiya

BACKGROUND: An estimated 32,000 children develop multidrug-resistant tuberculosis (MDR-TB; Mycobacterium tuberculosis resistant to isoniazid and rifampin) each year. Little is known about the optimal treatment for these children. METHODS AND FINDINGS: To inform the pediatric aspects of the revised World Health Organization (WHO) MDR-TB treatment guidelines, we performed a systematic review and individual patient data (IPD) meta-analysis, describing treatment outcomes in children treated for MDR-TB. To identify eligible reports we searched PubMed, LILACS, Embase, The Cochrane Library, PsychINFO, and BioMedCentral databases through 1 October 2014. To identify unpublished data, we reviewed conference abstracts, contacted experts in the field, and requested data through other routes, including at national and international conferences and through organizations working in pediatric MDR-TB. A cohort was eligible for inclusion if it included a minimum of three children (aged <15 years) who were treated for bacteriologically confirmed or clinically diagnosed MDR-TB, and if treatment outcomes were reported. The search yielded 2,772 reports; after review, 33 studies were eligible for inclusion, with IPD provided for 28 of these. All data were from published or unpublished observational cohorts. We analyzed demographic, clinical, and treatment factors as predictors of treatment outcome. In order to obtain adjusted estimates, we used a random-effects multivariable logistic regression (random intercept and random slope, unless specified otherwise) adjusted for the following covariates: age, sex, HIV infection, malnutrition, severe extrapulmonary disease, or the presence of severe disease on chest radiograph. We analyzed data from 975 children from 18 countries; 731 (75%) had bacteriologically confirmed and 244 (25%) had clinically diagnosed MDR-TB. The median age was 7.1 years. Of 910 (93%) children with documented HIV status, 359 (39%) were infected with HIV. When compared to clinically diagnosed patients, children with confirmed MDR-TB were more likely to be older, to be infected with HIV, to be malnourished, and to have severe tuberculosis (TB) on chest radiograph (p < 0.001 for all characteristics). Overall, 764 of 975 (78%) had a successful treatment outcome at the conclusion of therapy: 548/731 (75%) of confirmed and 216/244 (89%) of clinically diagnosed children (absolute difference 14%, 95% confidence interval [CI] 8%-19%, p < 0.001). Treatment was successful in only 56% of children with bacteriologically confirmed TB who were infected with HIV who did not receive any antiretroviral treatment (ART) during MDR-TB therapy, compared to 82% in children infected with HIV who received ART during MDR-TB therapy (absolute difference 26%, 95% CI 5%-48%, p = 0.006). In children with confirmed MDR-TB, the use of second-line injectable agents and high-dose isoniazid (15-20 mg/kg/day) were associated with treatment success (adjusted odds ratio [aOR] 2.9, 95% CI 1.0-8.3, p = 0.041 and aOR 5.9, 95% CI 1.7-20.5, p = 0.007, respectively). These findings for high-dose isoniazid may have been affected by site effect, as the majority of patients came from Cape Town. Limitations of this study include the difficulty of estimating the treatment effects of individual drugs within multidrug regimens, only observational cohort studies were available for inclusion, and treatment decisions were based on the clinician's perception of illness, with resulting potential for bias. CONCLUSIONS: This study suggests that children respond favorably to MDR-TB treatment. The low success rate in children infected with HIV who did not receive ART during their MDR-TB treatment highlights the need for ART in these children. Our findings of individual drug effects on treatment outcome should be further evaluated.

Hali tarjima qilinmagan

Identifikatorlar

Iqtiboslar va manbalar